Shares of CRISPR Therapeutics CRSP closed at $40.97 on Tuesday, close to their 52-week low of $36.52. This decline in CRSP ...

We recently published a list of 12 Most Shorted Stocks in 2025. In this article, we are going to take a look at where CRISPR ...

In the last year, some drugmakers have pulled back from the sector, including Pfizer, which recently stopped selling its gene ...

Zurcher Kantonalbank Zurich Cantonalbank raised its position in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 3.0% in ...

Farther Finance Advisors LLC boosted its holdings in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 34.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities & ...

We came across a bullish thesis on CRISPR Therapeutics AG (CRSP) on wallstreetbets Subreddit Page by MADD-Scientis. In this ...

Biotech is an area that may offer your portfolio growth today and earnings stability tomorrow. The idea is a biotech stock ...

CRISPR Therapeutics' stock faces challenges with slow Casgevy adoption and competition. See how CRSP stock remains a cautious ...

A pair of privately-held developers of editing-based therapies have some successes to show for their recent efforts to ...

CRISPR Therapeutics (CRSP) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock. Another industry also offers innovation and ...

Having established success in cancer, biopharma is now looking to leverage CAR T therapies against a new target, autoimmune ...

The Cambridge-based company touted the data as evidence of the first successful use of CRISPR gene editing to fix a ...